Is Chinook Therapeutics, Inc. (KDNY) a Buy, Sell, or Hold?
NASDAQ : KDNY
Chinook Therapeutics, Inc. — Stock Grades
$40.39 USD
$0.09 (0.22%)
- Volume
- 3.28M
- Average Volume
- 2.05M
- Market Capitalization
- $2.71B
- P/E Ratio
- -14.07
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $40.51
- Year Low
- $18.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.59
KDNY Stock Grades
| Date | Grading Company | Previous Grade | New Grade | Action |
|---|---|---|---|---|
| 2023-08-08 | Wedbush | Outperform | Neutral | Downgrade |
| 2023-08-07 | Wedbush | Outperform | Neutral | Downgrade |
| 2023-08-01 | Wells Fargo | Overweight | Equal Weight | Downgrade |
| 2023-07-31 | Wells Fargo | Overweight | Equal Weight | Downgrade |
| 2023-06-21 | HC Wainwright & Co. | Neutral | Neutral | Maintain |
| 2023-06-20 | HC Wainwright & Co. | Neutral | Neutral | Maintain |
| 2023-06-14 | Evercore ISI Group | Outperform | In Line | Downgrade |
| 2023-06-13 | SVB Leerink | Outperform | Perform | Downgrade |
| 2023-06-13 | Stifel | Buy | Hold | Downgrade |
| 2023-06-13 | Evercore ISI Group | Outperform | In Line | Downgrade |
| 2023-06-13 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2023-06-12 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2023-06-12 | SVB Leerink | Outperform | Perform | Downgrade |
| 2023-06-12 | Stifel | Buy | Hold | Downgrade |
| 2023-06-12 | William Blair | Outperform | Perform | Downgrade |
| 2023-06-12 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2023-06-12 | Guggenheim | Buy | Neutral | Downgrade |
| 2023-06-11 | Guggenheim | Buy | Neutral | Downgrade |
| 2023-06-11 | William Blair | Outperform | Perform | Downgrade |
| 2023-06-11 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2023-05-17 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2023-05-17 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2023-05-16 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2023-05-10 | Wedbush | Outperform | Outperform | Maintain |
| 2023-05-02 | Guggenheim | Buy | Buy | Maintain |
| 2023-05-02 | Cantor Fitzgerald | Overweight | Overweight | Maintain |
| 2023-05-01 | Guggenheim | Buy | Buy | Maintain |
| 2023-03-06 | Piper Sandler | Overweight | Overweight | Maintain |
| 2023-03-01 | Guggenheim | Buy | Buy | Maintain |
| 2023-02-28 | Oppenheimer | Outperform | Outperform | Maintain |
| 2023-02-28 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2023-02-27 | Oppenheimer | Outperform | Outperform | Maintain |
| 2023-02-21 | Oppenheimer | Outperform | Outperform | Maintain |
| 2023-02-20 | Oppenheimer | Outperform | Outperform | Maintain |